Small Molecules
17 February 2015
VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis17 February 2015
Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application For The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women17 February 2015
MediVector Completes Patient Enrollment in Two Phase 3 Studies of Favipiravir for Influenza17 February 2015
Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint16 February 2015
Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies16 February 2015
Galapagos reports positive Phase 1 results for GLPG169014 February 2015
FDA approves Lenvima for a type of thyroid cancer14 February 2015
Stealth BioTherapeutics Announces Promising Data on Ocuvia at 2015 Angiogenesis Conference14 February 2015
Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)12 February 2015
Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis12 February 2015
Anika Therapeutics Announces Regulatory Submissions with U.S. FDA and European Regulatory Authorities for Cingal11 February 2015
ChromaDex’s NIAGEN™ Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study11 February 2015
IOmet Pharma Demonstrates Superior In Vivo PK/PD Properties in Pre-Clinical IDO, TDO and Dual IDO/TDO Cancer Immunotherapy Programs11 February 2015
Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain11 February 2015
MerLion announces FDA approval of finafloxacin otic suspension11 February 2015
Edge Therapeutics Reports Initial Data from its Phase 1/2 NEWTON Trial for EG-1962 for Improvement of Outcomes after Ruptured Brain Aneurysm10 February 2015
Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program10 February 2015
FORUM Pharmaceuticals Inc. Initiates Phase 2a Clinical Trial of FRM-0334 in Frontotemporal Dementia with GRN Mutation10 February 2015
Hua Medicine Announces Positive Phase 1b Results in Diabetes With 4th-Generation Glucokinase Activator, Shows Robust 24-Hour Glucose Control10 February 2015
Strategic Science and Technologies Initiates Phase 1 Study to Evaluate Topical Sildenafil in Women with Female Sexual Arousal Disorder9 February 2015
GSK and Theravance announce start of phase III lung function study with ‘closed’ triple combination treatment FF/UMEC/VI for COPD9 February 2015
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports